表紙
市場調查報告書
商品編碼
1028946

全球癌細胞單克隆抗體市場報告:2021年版 - COVID-19擴大和到2030年前的變化

Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

出版日期: 按訂單生產 | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球癌細胞單克隆抗體市場相關調查,網羅市場特性,規模與成長,市場區隔,各地各國趨勢,競爭情形,市場佔有率,市場趨勢與策略。還有各地區的市場的實際成果與預測,及加入此市場的主要企業的簡介等資訊。

目錄

第1章 摘要整理

第2章 癌細胞單克隆抗體市場特徵

第3章 癌細胞單克隆抗體的市場趨勢與策略

第4章 COVID-19對癌細胞單克隆抗體的影響

第5章 癌細胞單克隆抗體的市場規模與成長

  • 全球癌細胞單克隆抗體市場實際成果,2015∼2020年,10億美元
    • 市場促進因素
    • 市場阻礙因素
  • 全球癌細胞單克隆抗體市場預測,2020∼2025年,2030年,10億美元
    • 市場促進因素
    • 市場阻礙因素

第6章 癌細胞單克隆抗體市場細分化

  • 全球癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • Bevacizumab(Avastin)
  • Rituximab(Rituxan)
  • Trastuzumab(Herceptin)
  • Cetuximab(爾必得舒(Erbitux))
  • Panitumumab
  • 其他
  • 全球癌細胞單克隆抗體市場,各用途市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • 乳癌
  • 血液癌症
  • 肝癌
  • 腦瘤
  • 大腸癌
  • 其他
  • 全球癌細胞單克隆抗體市場,各終端用戶市場區隔,歷史與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • 醫院及診療所
  • 研究
  • 藥局
  • 其他

第7章 癌細胞單克隆抗體市場各地區以及各國分析

  • 全球癌細胞單克隆抗體市場,各地區,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元
  • 全球癌細胞單克隆抗體市場,各國,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第8章 亞太地區的癌細胞單克隆抗體市場

  • 亞太地區的癌細胞單克隆抗體市場概要
  • 地區資訊,COVID-19的影響,市場資訊,背景資訊,政府的積極推動,法規,法規機關,主要的協會,免稅,公司稅結構,投資,主要企業
  • 亞太地區的癌細胞單克隆抗體市場,單株抗體療法市場區隔,歷史與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第9章 中國的癌細胞單克隆抗體市場

  • 中國的癌細胞單克隆抗體市場概要
  • 中國的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第10章 印度的癌細胞單克隆抗體市場

  • 印度的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第11章 日本的癌細胞單克隆抗體市場

  • 日本的癌細胞單克隆抗體市場,單株抗體療法市場區隔,歷史與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第12章 澳洲的癌細胞單克隆抗體市場

  • 澳洲的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第13章 印尼的癌細胞單克隆抗體市場

  • 印尼的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第14章 韓國的癌細胞單克隆抗體市場

  • 韓國的癌細胞單克隆抗體市場,單株抗體療法市場區隔,歷史與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第15章 西歐的癌細胞單克隆抗體市場

  • 西歐的癌細胞單克隆抗體市場概要
  • 西歐的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第16章 英國的癌細胞單克隆抗體市場

  • 英國的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第17章 德國的癌細胞單克隆抗體市場

  • 德國的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第18章 法國的癌細胞單克隆抗體市場

  • 法國的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第19章 東歐的癌細胞單克隆抗體市場

  • 東歐的癌細胞單克隆抗體市場概要
  • 東歐的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第20章 俄羅斯的癌細胞單克隆抗體市場

  • 俄羅斯的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第21章 北美的癌細胞單克隆抗體市場

  • 北美的癌細胞單克隆抗體市場概要
  • 北美的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第22章 美國的癌細胞單克隆抗體市場

  • 美國的癌細胞單克隆抗體市場概要
  • 美國的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第23章 南美的癌細胞單克隆抗體市場

  • 南美的癌細胞單克隆抗體市場概要
  • 南美的癌細胞單克隆抗體市場,單株抗體療法市場區隔,歷史與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第24章 巴西的癌細胞單克隆抗體市場

  • 巴西的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第25章 中東的癌細胞單克隆抗體市場

  • 中東的癌細胞單克隆抗體市場概要
  • 中東的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第26章 非洲的癌細胞單克隆抗體市場

  • 非洲的癌細胞單克隆抗體市場概要
  • 非洲的癌細胞單克隆抗體市場,單株抗體療法市場區隔,實際成果與預測,2015∼2020年,2020∼2025年,2030年,10億美元

第27章 癌細胞單克隆抗體市場競爭情形和企業簡介

  • 癌細胞單克隆抗體市場競爭情形
  • 癌細胞單克隆抗體市場企業簡介
    • Amgen
    • Bristol Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Genmab AS

第28章 癌細胞單克隆抗體開發平台分析

第29章 癌細胞單克隆抗體市場上主要合併和收購

第30章 癌細胞單克隆抗體市場未來展望和潛在性分析

第31章 附錄

目錄
Product Code: h971

Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change to 2030 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global cancer monoclonal antibodies (mabs) market.

This report focuses on cancer monoclonal antibodies (mabs) market which is experiencing strong growth. The report gives a guide to the cancer monoclonal antibodies (mabs) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the cancer monoclonal antibodies (mabs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cancer Monoclonal Antibodies (mAbs) market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider cancer monoclonal antibodies (mabs) market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The cancer monoclonal antibodies (mabs) market section of the report gives context. It compares the cancer monoclonal antibodies (mabs) market with other segments of the cancer monoclonal antibodies (mabs) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, cancer monoclonal antibodies (mabs) indicators comparison.

Scope

Markets Covered:

1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Others

2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Others

3) By End User: Hospitals And Clinics; Research Laboratories; Pharmacies; Others

Companies Mentioned: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genmab AS

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Executive Summary

2. Cancer Monoclonal Antibodies Market Characteristics

3. Cancer Monoclonal Antibodies Market Trends And Strategies

4. Impact Of COVID-19 On Cancer Monoclonal Antibodies

5. Cancer Monoclonal Antibodies Market Size And Growth

  • 5.1. Global Cancer Monoclonal Antibodies Historic Market, 2015-2020, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Cancer Monoclonal Antibodies Forecast Market, 2020-2025F, 2030F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Cancer Monoclonal Antibodies Market Segmentation

  • 6.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Bevacizumab (Avastin)
  • Rituximab (Rituxan)
  • Trastuzumab (Herceptin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Others
  • 6.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Others
  • 6.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals and Clinics
  • Research Laboratories
  • Pharmacies
  • Others

7. Cancer Monoclonal Antibodies Market Regional And Country Analysis

  • 7.1. Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • 7.2. Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Cancer Monoclonal Antibodies Market

  • 8.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Cancer Monoclonal Antibodies Market

  • 9.1. China Cancer Monoclonal Antibodies Market Overview
  • 9.2. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Cancer Monoclonal Antibodies Market

  • 10.1. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Cancer Monoclonal Antibodies Market

  • 11.1. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Cancer Monoclonal Antibodies Market

  • 12.1. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Cancer Monoclonal Antibodies Market

  • 13.1. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Cancer Monoclonal Antibodies Market

  • 14.1. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Cancer Monoclonal Antibodies Market

  • 15.1. Western Europe Cancer Monoclonal Antibodies Market Overview
  • 15.2. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Cancer Monoclonal Antibodies Market

  • 16.1. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Cancer Monoclonal Antibodies Market

  • 17.1. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Cancer Monoclonal Antibodies Market

  • 18.3. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Cancer Monoclonal Antibodies Market

  • 19.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview
  • 19.2. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Cancer Monoclonal Antibodies Market

  • 20.1. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Cancer Monoclonal Antibodies Market

  • 21.1. North America Cancer Monoclonal Antibodies Market Overview
  • 21.2. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Cancer Monoclonal Antibodies Market

  • 22.1. USA Cancer Monoclonal Antibodies Market Overview
  • 22.2. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Cancer Monoclonal Antibodies Market

  • 23.1. South America Cancer Monoclonal Antibodies Market Overview
  • 23.2. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Cancer Monoclonal Antibodies Market

  • 24.1. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Cancer Monoclonal Antibodies Market

  • 25.1. Middle East Cancer Monoclonal Antibodies Market Overview
  • 25.2. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Cancer Monoclonal Antibodies Market

  • 26.1. Africa Cancer Monoclonal Antibodies Market Overview
  • 26.2. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

  • 27.1. Cancer Monoclonal Antibodies Market Competitive Landscape
  • 27.2. Cancer Monoclonal Antibodies Market Company Profiles
    • 27.2.1. Amgen
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Bristol Myers Squibb Company
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Eli Lilly and Company
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. F. Hoffmann-La Roche Ltd
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Genmab AS
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Cancer Monoclonal Antibodies Pipeline Analysis

29. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

30. Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Research Inquiries
  • 31.4. The Business Research Company
  • 31.5. Copyright And Disclaimer